<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867785</url>
  </required_header>
  <id_info>
    <org_study_id>17774</org_study_id>
    <secondary_id>J1I-MC-GZBD</secondary_id>
    <nct_id>NCT04867785</nct_id>
  </id_info>
  <brief_title>A Study of LY3437943 in Participants With Type 2 Diabetes</brief_title>
  <official_title>A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in&#xD;
      participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on&#xD;
      diet and exercise alone or on a stable dose of metformin. This study will last about 43&#xD;
      weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
    <description>Change in HbA1c (%) from baseline in LY3437943 relative to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HbA1c</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
    <description>Change in HbA1c (%) from baseline in LY3437943 relative to dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HbA1c</measure>
    <time_frame>Baseline, 36 Weeks</time_frame>
    <description>Change in HbA1c (%) from baseline in LY3437943 relative to placebo and dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participant Reaching HbA1c &lt;7.0%</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants reaching HbA1c &lt;7.0% in LY3437943 relative to placebo and dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participant Reaching HbA1c &lt;7.0%</measure>
    <time_frame>Week 36</time_frame>
    <description>Percentage of participants reaching HbA1c &lt;7.0% in LY3437943 relative to placebo and dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Blood Glucose (FBG)</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
    <description>Change in FBG in LY3437943 relative to placebo and dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Blood Glucose (FBG)</measure>
    <time_frame>Baseline, 36 Weeks</time_frame>
    <description>Change in FBG in LY3437943 relative to placebo and dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
    <description>Change in body weight in LY3437943 relative to placebo and dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline, 36 Weeks</time_frame>
    <description>Change in body weight in LY3437943 relative to placebo and dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) Plasma concentration of LY3437943</measure>
    <time_frame>Predose: Week 0, 1, 4, 12, 24, 30, 36 Postdose: Week 2, 8, 16, 20</time_frame>
    <description>Plasma concentration of LY3437943 will be assessed</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>LY3437943 Maintenance Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered by subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3437943 Maintenance Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered by SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3437943 Maintenance Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered by SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3437943 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered by SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dulaglutide will be given SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be given SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3437943</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3437943 Dose 4</arm_group_label>
    <arm_group_label>LY3437943 Maintenance Dose 1</arm_group_label>
    <arm_group_label>LY3437943 Maintenance Dose 2</arm_group_label>
    <arm_group_label>LY3437943 Maintenance Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Dulaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have Type 2 Diabetes (T2D)&#xD;
&#xD;
          -  Have an HbA1c value at screening of ≥7.0% and ≤10.5% and treated with diet and&#xD;
             exercise alone or with a stable dose of metformin (either immediate release or&#xD;
             extended release, 1000 milligram (mg)/day and not more than the locally approved dose)&#xD;
             for at least 3 months prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have type 1 diabetes mellitus (T1DM)&#xD;
&#xD;
          -  Have ketoacidosis&#xD;
&#xD;
          -  Have retinopathy, maculopathy&#xD;
&#xD;
          -  Have history of pancreatitis&#xD;
&#xD;
          -  Have obesity induced by other endocrine disorders&#xD;
&#xD;
          -  Have uncontrolled hypertension&#xD;
&#xD;
          -  Have acute or chronic hepatitis&#xD;
&#xD;
          -  Have chronic kidney disease&#xD;
&#xD;
          -  Have an autoimmune abnormality for example, lupus or rheumatoid arthritis&#xD;
&#xD;
          -  Have an active or untreated malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-2559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Syed Research Consultants Llc</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aaron W Karr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Fernando Valley Health Institute</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>818-222-6868</phone>
    </contact>
    <investigator>
      <last_name>Dan Streja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Endocrine, Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>559-261-0992</phone>
    </contact>
    <investigator>
      <last_name>Paul Carlton Norwood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>323-588-1968</phone>
    </contact>
    <investigator>
      <last_name>Stanley H. Hsia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>909-590-8409</phone>
    </contact>
    <investigator>
      <last_name>Rizwana H Mohseni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>8185326880</phone>
    </contact>
    <investigator>
      <last_name>Robert Allen Jenders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anderson Clinical Research</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>9097929007</phone>
    </contact>
    <investigator>
      <last_name>Donald Lee Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>951-374-1190</phone>
    </contact>
    <investigator>
      <last_name>Sarah Lavery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-278-3647</phone>
    </contact>
    <investigator>
      <last_name>Stacey Layle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute (NRI) - Santa Ana</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>213-413-2500</phone>
    </contact>
    <investigator>
      <last_name>Mark T. Leibowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>925-930-7267</phone>
    </contact>
    <investigator>
      <last_name>Helen L Stacey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida Clinical Research Institute</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-582-7007</phone>
    </contact>
    <investigator>
      <last_name>Juan Loy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-264-2155</phone>
    </contact>
    <investigator>
      <last_name>Tanya R Bogle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Encore Medical Research - Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-400-1725</phone>
    </contact>
    <investigator>
      <last_name>Sandro Bacchelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Trials</name>
      <address>
        <city>Blackfoot</city>
        <state>Idaho</state>
        <zip>83221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>208-643-0006</phone>
    </contact>
    <investigator>
      <last_name>Gary W Soucie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humphreys Diabetes Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>208-287-9429</phone>
    </contact>
    <investigator>
      <last_name>Sherwin D'Souza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Clinical Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>208-522-6005</phone>
    </contact>
    <investigator>
      <last_name>Carl D Vance</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Trials</name>
      <address>
        <city>Rexburg</city>
        <state>Idaho</state>
        <zip>83440</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>208-643-0006</phone>
    </contact>
    <investigator>
      <last_name>Gary W Soucie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Diabetes and Endocrinology Research Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>515-329-6800</phone>
    </contact>
    <investigator>
      <last_name>Anuj Bhargava</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinic</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7853680428</phone>
    </contact>
    <investigator>
      <last_name>Alan Glenn Wynne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Group</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>410-730-3399</phone>
    </contact>
    <investigator>
      <last_name>Steven A. Geller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MediSync Clinical Research</name>
      <address>
        <city>Petal</city>
        <state>Mississippi</state>
        <zip>39465</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>601-296-2987</phone>
    </contact>
    <investigator>
      <last_name>Rambod Rouhbakhsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinvest Research LLC</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>417-883-7889</phone>
    </contact>
    <investigator>
      <last_name>David Gregory True</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Logan Health Research</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>406-751-4171</phone>
    </contact>
    <investigator>
      <last_name>Jose de Souza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lillestol Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael J Lillestol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intend Research, LLC</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-701-8999</phone>
    </contact>
    <investigator>
      <last_name>Lisa Connery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heritage Valley Medical Group, Inc.</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>724-774-7743</phone>
    </contact>
    <investigator>
      <last_name>Michael J Oliver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-650-6155</phone>
    </contact>
    <investigator>
      <last_name>Bryce A. Palchick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research, LLC</name>
      <address>
        <city>Smithfield</city>
        <state>Pennsylvania</state>
        <zip>15478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>724-569-8100</phone>
    </contact>
    <investigator>
      <last_name>Marcy Goisse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>724-438-1479</phone>
    </contact>
    <investigator>
      <last_name>Joseph M Labuda II</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Research Center of The Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>864-626-3117</phone>
    </contact>
    <investigator>
      <last_name>Harlicia Farley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-566-7799</phone>
    </contact>
    <investigator>
      <last_name>Julio Rosenstock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetes and Thyroid Center of Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>817-263-0007</phone>
    </contact>
    <investigator>
      <last_name>Anjanette Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrine Ips, Pllc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-973-3415</phone>
    </contact>
    <investigator>
      <last_name>Amer S Al-Karadsheh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laila A Hassan, MD, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>2819443610</phone>
    </contact>
    <investigator>
      <last_name>Amir Ali Hassan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Endocrinology Associates</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sumana Gangi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Hills Family Medicine/North Hills Medical Research</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>817-595-3399</phone>
    </contact>
    <investigator>
      <last_name>John Gabriel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>425-251-1720</phone>
    </contact>
    <investigator>
      <last_name>Leslie J Klaff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universal Research Group</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>253-882-1070</phone>
    </contact>
    <investigator>
      <last_name>Sabrina Ann Benjamin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Vancouver Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>360-397-3388</phone>
    </contact>
    <investigator>
      <last_name>Stacey Condren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research, LLC</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7872696590</phone>
    </contact>
    <investigator>
      <last_name>Angel Luis Comulada-Rivera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manati Center for Clinical Research</name>
      <address>
        <city>Manati</city>
        <zip>674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7879047700</phone>
    </contact>
    <investigator>
      <last_name>Ramon Ortiz-Carrasquillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Latin Clinical Trial Center</name>
      <address>
        <city>San Juan</city>
        <zip>909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7879859911</phone>
    </contact>
    <investigator>
      <last_name>Alex Gonzalez-Bossolo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/6tv02tRhvMamBP866x6OPm</url>
    <description>A Study of LY3437943 in Participants With Type 2 Diabetes</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

